AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01069367 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Emulsion, Cell Culture-based, influenza HA vaccine H1N1
Description: Cell-derived A/H1N1 influenza HA vaccine (0.25 mL as injection volume)
Study NCT01827241 — intervention group
Intervention type: OTHER
Intervention: Chart Review
Description: Retrospective and prospective data review of colonoscopy procedures, examination findings, resection techniques, and pathology reports.
Study NCT02957474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GED-0301
Study NCT01119313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active
Description: Active, once daily
Study NCT01217905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7687
Description: Oral suspension
Study NCT04175405 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irradiation of implants with 635nm laser
Description: Irradiation of implants with 635nm laser with a dose of 10J
Study NCT03092726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8062
Description: ASP8062 30 mg was administered orally as a single daily dose, taken preferably in the morning with or without food.
Study NCT03092726 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was administered orally as a single daily dose, taken preferably in the morning with or without food.
Study NCT02957474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Study NCT02062242 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transvaginal electrical stimulation
Description: The current employed is biphasic and the stimulation parameters are: frequency of 50 Hz, pulse width of 200 microseconds, contraction time (Ton) of 5 seconds and relaxation time (Toff) of 10 seconds. The current intensity is defined according to the tolerance of patient and the total stimulation time is 20 minutes.
Study NCT02062242 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palpation
Description: The patient is positioned supine with the lower limbs bent and feet flat on the stretcher. The examiner will hold vaginal palpation and to request her the contraction of PFM. It will be requested 3 sets of 10 contractions with a rest period between contractions. There are two minutes a rest period between sets.
Study NCT02062242 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palpation with posterior pelvic tilt
Description: The patient is positioned supine with the lower limbs bent and feet flat on the stretcher. The examiner will hold vaginal palpation and to request her the contraction of PFM associated with posterior pelvic tilt and contraction of accessory muscles. It will be requested 3 sets of 10 contractions with a rest period between contractions. There are two minutes a rest period between sets.
Study NCT02062242 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: The patient receive verbal instructions related to the pelvic floor and its contraction.
Study NCT02255760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI3902 - Dose 1
Description: Participants will receive a single IV dose of MEDI3902 infused for a minimum of 13 minutes on Day 1.
Study NCT02255760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI3902 - Dose 2
Description: Participants will receive a single IV dose of MEDI3902 infused for a minimum of 38 minutes on Day 1.
Study NCT02255760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI3902 - Dose 3
Description: Participants will receive a single IV dose of MEDI3902 infused for a minimum of 75 minutes on Day 1.
Study NCT02255760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI3902 - Dose 4
Description: Participants will received a single IV dose of MEDI3902 infused for a minimum of 150 minutes on Day 1.
Study NCT02255760 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a single dose of placebo by IV infusion up to a maximum of 12 hours.
Study NCT02608372 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LD
Description: Participants ingested 5 g of Laminaria digitata followed by 30 g of corn starch mixed with 200 mL of water.
Study NCT01956747 — intervention group
Intervention type: PROCEDURE
Intervention: venapunction
Study NCT01956747 — intervention group
Intervention type: PROCEDURE
Intervention: bone marrow punction
Study NCT02608372 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UP
Description: Participants ingested 5 g of Undaria pinnatifida followed by 30 g of corn starch mixed with 200 mL of water.
Study NCT02608372 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CTR
Description: Participants ingested 30 g of corn starch and 1 g of pea protein powder mixed with 200 mL of water.
Study NCT02574767 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling
Description: Obese pregnant women from PHCC randomized to this group will receive Home-based Diet \& Physical activity (PA) counseling. Home-based intervention will consider 2 home visits of one hour of duration. During this session dietary educational and behavioral will be discussed with the participants and their families tailoring the contents based on the specific contexts.
Study NCT02574767 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PUFA Supplementation
Description: Obese pregnant women from PHCC randomized to this group will receive n3LC-PUFAs oral supplementation based on Schizochytrium oil (S-oil) containing 800 mg docosahexaenoic (DHA) acid/day, which will be administered as capsular preparations containing 200 mg DHA/capsule (4 capsules/day).
Study NCT04344704 — intervention group
Intervention type: OTHER
Intervention: Single chamber DAI device with floating atrial dipole
Description: DAI for the detection of atrial signals with optimized programming, using Smart, Onset \& Stability, and Morphmatch methods
Study NCT00826488 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Digital Breast Tomosynthesis
Description: Women with a positive screening mammogram called back for additional views will be asked to undergo an additional Digital Breast Tomosynthesis (3D mammogram) on the affected breast. Radiation dose is somewhat less than that of a screening mammogram.
Study NCT02366793 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accessory joint mobilization
Description: Three kinds of humeral head slides: anterior, posterior and caudal slides. Subjects remained in supine position during the whole treatment. The techniques were applied in a rhythmical way, with 2 seconds of slide/traction and then a 2-second break. Each technique was carried out for 2 minutes.
Study NCT02366793 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nerve mobilization
Description: Neural tissue longitudinal slide using the median neurodynamic test 1 (MNT1) that was described by Butler. The proximal parameters (scapular depression, abduction and humeral external rotation) were introduced with maximum neural tension. On the other hand, the distal parameters (supination, elbow extension, wrist and fingers extension) received the remaining tension that the neural tissue allowed. The parameters were introduced sequentially in the order exposed
Study NCT04026945 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lidocaine
Description: Sustained-release lidocaine injection
Study NCT04399057 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: shear Wave Elastosonography
Description: both the left cavernous body and the right cavernous body are ideally divided longitudinally into three sections: proximal, middle and distal. subsequently for each section of the corpora cavernosa the stiffness of the tissue is calculated by means of a specific Region Of Interest (ROI). the result is expressed in Kilopascals and in a color scale. when registering the stiffness the patient is asked to hold their breath.
Study NCT03554304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WCK 5222
Description: FEP-ZID IV solution administered as either a 30- or 60-minute IV infusion)
Study NCT03554304 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV placebo matched to WCK 5222 / Moxifloxacin IV solution
Description: Placebo (IV placebo matched to FEP-ZID IV solution) and~1 placebo capsule matched to moxifloxacin overencapsulated tablet
Study NCT03554304 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV placebo matched to WCK 5222 / Moxifloxacin IV solution
Description: Placebo (IV placebo matched to FEP-ZID IV solution) and~1 placebo capsule matched to moxifloxacin overencapsulated tablet
Study NCT03554304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV placebo matched to WCK 5222 / Moxifloxacin IV solution
Description: Placebo (IV placebo matched to FEP-ZID IV solution) and~1 placebo capsule matched to moxifloxacin overencapsulated tablet
Study NCT03554304 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 400-mg
Description: Moxifloxacin 400-mg positive control (overencapsulated tablet)
Study NCT01113190 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computer-delivered Brief Intervention (CBI)
Description: The multimedia, interactive Computer BI (CBI) condition will be delivered using tablet computers. The content and format will be easily negotiated by participants. The proposed CBI condition will use actors with 'green screen' to deliver scripted therapist content that will be highly tailored to individual responses. 'Green screens' are standard recording formats that allow for inserting engaging background and other overlays onto recorded material. This program will be viewed on a touch screen tablet computer with audio delivered via headphones. The CBI will be designed in a therapist video-delivered interactive style, that provides tailoring options for reviewing patient goals, providing feedback regarding substance use patterns and consequences, completing a decisional balance exercise, and formulating a change plan. It requires active participation and is not a passive video that is merely viewed.
Study NCT01113190 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervener-delivered Brief Intervention (IBI)
Description: IBI is a 30-minute intervention session with a master's-level clinician. The interventions will include FRAMES (Miller \& Rollnick, 2002): personalized Feedback (regarding substance use, risk factors), emphasis on Responsibility for change, Advice, Menu of options, Empathic clinical behaviors, and support of Self-Efficacy regarding making changes. The interventions are designed to address the primary target behavior of drug use, and will include a tailored review of participants' goals/values, feedback regarding their present substance use patterns and consequences, developing a discrepancy between their substance use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan tailored for each participant. IBI will be highly individualized to participants' goals, values and substance use, and will will follow similar session outlines and length of delivery as the CBI sessions.
Study NCT01113190 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adapted Motivational Enhancement Therapy (AMET)
Description: This session will have a similar general outline to the sessions conducted in the ED, including a review of participants' goals and values, and a review of their substance use and consequences, use of decisional balance exercises as indicated, and review and modification of their change plan. For the AMET intervention, the intervener (at least master's level) will conduct a single session (\~30-45 minutes) in the community (HMC ED or our community research office). The therapist will be able to tailor their approach to each individual's needs and motivational state.
Study NCT02574767 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine diet & PA
Description: Obese pregnant women from PHCC randomized to this group will receive will receive routine diet \& PA counseling (i.e. they will receive the standard education sessions included in the prenatal controls at PHCC but no home-based counseling sessions).
Study NCT02574767 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Routine diet & PA
Description: Obese pregnant women from PHCC randomized to this group will receive will receive routine diet \& PA counseling (i.e. they will receive the standard education sessions included in the prenatal controls at PHCC but no home-based counseling sessions).
Study NCT02574767 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PUFA placebo
Description: Obese pregnant women from PHCC randomized to this group will receive capsular preparations containing 50 mg DHA/capsule (4 capsules/day), given that evidence suggests that it would be unethical not to provide DHA during pregnancy. Placebo will be delivered in the same way that the n3LC-PUFA supplementation.
Study NCT02574767 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PUFA placebo
Description: Obese pregnant women from PHCC randomized to this group will receive capsular preparations containing 50 mg DHA/capsule (4 capsules/day), given that evidence suggests that it would be unethical not to provide DHA during pregnancy. Placebo will be delivered in the same way that the n3LC-PUFA supplementation.
Study NCT01113190 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Description: The EUC group will receive brief advice to change their drug use, as well as a booklet including information on community support groups, location of substance use treatment centers, mental health services, suicide prevention hotlines, risk of injecting drugs including HIV and hepatitis and HIV prevention and testing information.
Study NCT04448366 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: Patients in the CBT group will receive usual care. In addition, they will undergo one pre-surgery and six post-surgery face-to-face sessions of CBT. In the pre-surgery session, management of expectations towards surgery will be addressed. In the six post-surgery sessions, attention will be paid to psycho-education concerning the biological link between endometriosis-related pain and stress, relaxation training, cognitive stress management, and management of anxiety, catastrophizing and hypervigilance. The CBT sessions will be coordinated by a registered psychotherapist who is experienced in CBT and has knowledge about endometriosis. All CBT will be individual sessions.
Study NCT01948661 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mirtoselect® + Meriva®
Study NCT01948661 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02038972 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cells
Description: The subjects autologous stem cells banked at Cord Blood Registry will be infused intravenously by gravity.
Study NCT01113177 — intervention group
Intervention type: DEVICE
Intervention: Distraction splint therapy
Description: After the diagnosis of unilateral TMJ arthritis with clinical asymmetric mandibular growth deviations the JIA patients are offered treatment with a distraction splint. The appliance consists of an acrylic splint (distraction splint) covering the occlusal surfaces of the teeth in the upper or lower dental arch. The height of the splint is thereafter gradually increased every 6th to 10th weeks in order to optimize the mandible growth in the affected side and thereby reduce the overall asymmetric mandibular growth pattern(non-surgical distraction of the TMJ and mandibular condyle).
Study NCT03763695 — intervention group
Intervention type: OTHER
Intervention: Measures for the VAP prevention in the PICU
Description: Oral hygiene care (i.e chlorhexidine swab); clean and dry ventilator circuits; head positioning at 45 degrees.
Study NCT03763695 — intervention group
Intervention type: OTHER
Intervention: Evaluation of VAP incidence before the protocol introduction
Description: evaluation of VAP incidence in our pediatric population of intensive care patients before the implementation of the protocol for VAP prevention
Study NCT02977429 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: standardized fluid therapy
Description: The patients with ScvO2 \<70% will receive the standardized fluid therapy for 6 hours.
Study NCT02977429 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional fluid therapy
Description: The patients with ScvO2 ≥ 70% will receive the conventional fluid therapy.
Study NCT02679937 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fit4Duty
Description: Small (\<9) participant-driven groups meet weekly for 6, 1 hour sessions. Participants design small, gradual healthy lifestyle change plans with added verbal, written, and behavioral exercises designed to elicit dissonance regarding engaging in unhealthy eating and sedentary practices. Participants are asked to voluntarily discuss the health, interpersonal and societal costs of obesity, an unhealthy diet, and sedentary behavior, as well as the benefits of leanness, a healthy diet, and regular physical activity.
Study NCT02679937 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition Education
Description: Two, 50 minute educational videos address basic concepts of healthy nutrition and weight management reviewing topics such as macro and micronutrients, the virtue of whole grains, fruit, vegetables and superfoods, the dangers of dehydration and vitamin deficiency. The role of poor eating habits, lack of exercise and cultural and technological issues in America's obesity epidemic is examined. A basic understanding of energy balance is conveyed. The role of nutritional supplements is addressed.
Study NCT02676895 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GVGH S. sonnei (1790GAHB) vaccine 25 μg
Description: Two injections of the study vaccine were administered 28 days apart.
Study NCT03238755 — intervention group
Intervention type: OTHER
Intervention: Cardiac MRI/MRS
Description: whole blood, plasma, and serum
Study NCT01336595 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zirconium (Zirconium Genesis II)
Description: Oxidized Zirconium femoral component of Genesis II TKR system is used.
Study NCT02669771 — intervention group
Intervention type: DRUG
Intervention: enzalutamide
Description: oral
Study NCT02676895 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GVGH S. sonnei (1790GAHB) vaccine 100 μg
Description: Two injections of the study vaccine were administered 28 days apart.
Study NCT02676895 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menveo
Description: One injection of Menveo was administered in subjects in the Control Group.
Study NCT01336595 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cobalt-Chrome (Cobalt Chrome Genesis II)
Description: Cobalt Chrome Femoral Component of Genesis II TKR system is used
Study NCT03115125 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Describe for the first time the kinetics of evolution in proportion of the circulating Brég in patients with severe septic state, at times D0, D2, D7 and D14 of hospitalization in medical reanimation.
Description: Describe for the first time the kinetics of evolution in proportion of the circulating Brég in patients with severe septic state, at times D0, D2, D7 and D14 (or on leaving the service if before D14) of hospitalization in medical reanimation.
Study NCT02057068 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SLEEP-E Dyads Intervention
Description: Described in arm/group description
Study NCT01128166 — intervention group
Intervention type: DEVICE
Intervention: COGNIS CRT-D
Description: Patients with existing or newly implanted COGNIS® CRT-D pulse generators (PG)are enrolled in the study. PG is modified by the download of investigational software called Sensor Research Device-1™ (SRD-1). The goal of the SRD-1 system is to collect sensor data without affecting the delivered CRT-D therapy. This is accomplished through the conversion of an implanted COGNIS PG into a SRD-1 PG by downloading investigational software. Only a market approved COGNIS model N119/N120/P107/P108 device may be converted to a SRD-1 investigational device. There will be no PG hardware changes resulting from the conversion.
Study NCT03625297 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: shelter cat
Description: families will adopt a shelter cat
Study NCT03385408 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIRO® 3.0
Description: Patients will receive pulsed Nd:YAG (yttrium aluminum garnet) laser, produced by HIRO 3.0 device (ASA, Vicenza, Italy). The total energy deliver to the patient during one session will be 3.000 J through three phases of treatment. HILT will be applied for a total of 4 weeks (three sessions/week).
Study NCT03385408 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham laser
Description: For sham laser, the patient will attended the physical therapy clinic three times a week for 4 weeks and receive sham laser. It is applies the same time than experimental one but with 0 W.
Study NCT00210405 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sprinkles containing mulitple micronutrients
Study NCT00210405 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education/communication on use of micronutrient sprinkles
Study NCT00210405 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fortified food aid (corn-soy blend)
Description: This intervention was part of the overall food assisted maternal and child health and nutrition program, and included fortified food aid commodities. Corn soy blend was targeted to the child, while the family also received wheat, lentils and oil.
Study NCT00210405 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortified food aid (corn-soy blend)
Description: This intervention was part of the overall food assisted maternal and child health and nutrition program, and included fortified food aid commodities. Corn soy blend was targeted to the child, while the family also received wheat, lentils and oil.